Drug-induced torsades de pointes: The evolving role of pharmacogenetics

Heart Rhythm

Volumn 2, Issue 11 SUPPL. 2, 2005, Pages

  Fitzgerald, Patrick T ^a   Ackerman, Michael J ^a,b,c,d  

^a Division of Pediatric Cardiology   (United States)

^b Mayo Clinic   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

HERG potassium channel; Ion channels; Long QT syndrome; Pharmacogenetics; Pharmacogenomics; Polymorphisms; Torsades de pointes

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; CLARITHROMYCIN; DOFETILIDE; DROPERIDOL; GREPAFLOXACIN; HALOFANTRINE; IBUTILIDE; ITRACONAZOLE; KETOCONAZOLE; LEVACETYLMETHADOL; MESORIDAZINE; MIBEFRADIL; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; PROTEINASE INHIBITOR; QUINIDINE; ROFECOXIB; SERTINDOLE; SPARFLOXACIN; TERFENADINE; TERODILINE; THIORIDAZINE; ZIPRASIDONE;

ARRHYTHMOGENESIS; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; LONG QT SYNDROME; PHARMACOGENETICS; PNEUMONIA; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TORSADE DES POINTES;

EID: 27744471093     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2005.08.007     Document Type: Article

References (51)

1. K.E. Lasser P.D. Allen S.J. Woolhandler D.U. Himmelstein S.M. Wolfe D.H. Bor Timing of new black box warnings and withdrawals for prescription medications JAMA 287 2002 2215-2220
2. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013-1022
3. B.D. Anson J.G. Weaver M.J. Ackerman O. Akinsete K. Henry C.T. January A.D. Badley Blockade of HERG channels by HIV protease inhibitors Lancet 365 2005 682-686
4. J.A. DiMasi R.W. Hansen H.G. Grabowski The price of innovation new estimates of drug development costs J Health Econ 22 2003 151-185
5. Merck profit drops 21% on Vioxx troubles 2005 USA Today, January 25
6. P. Ahmed J. Gardella S. Nanda Wealth effect of drug withdrawals on firms and their competitors Financial 31 2002 21-41 Management 31 2002 21-41
7. W. Haverkamp G. Breithardt A.J. Camm M.J. Janse M.R. Rosen C. Antzelevitch D. Escande M. Franz M. Malik A. Moss R. Shah The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology Cardiovasc Res 47 2000 219-233
8. R.R. Fenichel M. Malik C. Antzelevitch M. Sanguinetti D.M. Roden S.G. Priori J.N. Ruskin R.J. Lipicky L.R. Cantilena Independent Academic Task Drug-induced torsades de pointes and implications for drug development J Cardiovasc Electrophysiol 15 2004 475-495
9. De Ponti F, Poluzzi E, Vaccheri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G, Montanaro N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002;54: 171-177
10. FDA. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Center for Drug Evaluation and Research, 2004
11. European Agency for the Evaluation of Medicinal Products The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2004 Committee for Proprietary Medicinal Products
12. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348: 1866-1874
13. R.L. Woosely M. Sale QT interval: A measure of drug action Am J Cardiol 72 1993 36B-43B
14. R. Lazzara Amiodarone and torsade de pointes Ann Intern Med 111 1989 549-551
15. D.M. Roden Acquired long QT syndromes and the risk of proarrhythmia J Cardiovasc Electrophysiol 11 2000 938-940
16. M.C. Sanguinetti J.S. Mitcheson Predicting drug-hERG channel interactions that cause acquired long QT syndrome Trends Pharmacol Sci 26 2005 119-124
17. P.K. Honig D.C. Wortham K. Zamani D.P. Conner J.C. Mullin L.R. Cantilena Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences JAMA 269 1993 1513-1518
18. A.M. Carlson L.S. Morris Coprescription of terfenadine and erythromycin or ketoconazole: An assessment of potential harm J Am Pharm Assoc NS36 1996 263-269
19. D. Thompson G. Oster Use of terfenadine and contraindicated drugs JAMA 275 1996 1339-1341
20. K. Fujita Food-drug interactions via human cytochrome P450 3A (CYP3A) Drug Metab Drug Interact 20 2004 195-217
21. M.F. Paine A.B. Criss P.B. Watkins Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition J Pharmacol Exp Ther 312 2005 1151-1160
22. S.G. Priori Exploring the hidden danger of noncardiac drugs J Cardiovasc Electrophysiol 9 1998 1114-1116
23. D.M. Roden Genetic polymorphisms, drugs, and proarrhythmia J Interven Card Electrophysiol 9 2003 131-135
24. M.E. Curran I. Splawski K.W. Timothy G.M. Vincent E.D. Green M.T. Keating A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 80 1995 795-803
25. M.J. Ackerman The long QT syndrome: Ion channel diseases of the heart Mayo Clin Proc 73 1998 250-269
26. M.J. Ackerman Cardiac channelopathies: It's in the genes Nat Med 10 2004 463-464
27. I. Splawski J. Shen K.W. Timothy M.H. Lehmann S. Priori J.L. Robinson A.J. Moss P.J. Schwartz J.A. Towbin G.M. Vincent M.T. Keating Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Circulation 102 2000 1178-1185
28. D.J. Tester M.L. Will C.M. Haglund M.J. Ackerman Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing Heart Rhythm 2 2005 507-517
29. A.A. Wilde R.J. Jongbloed P.A. Doevendans D.R. Duren R.N. Hauer I.M. van Langen J.P. van Tintelen H.J. Smeets H. Meyer J.L. Geelen Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1) J Am Coll Cardiol 33 1999 327-332
30. S.G. Priori C. Napolitano P.J. Schwartz Low penetrance in the long-QT syndrome: Clinical impact Circulation 99 1999 529-533
31. P. Yang H. Kanki B. Drolet T. Yang J. Wei P.C. Viswanathan S.H. Hohnloser W. Shimizu P.J. Schwartz M. Stanton K.T. Murray K. Norris A.L. George Jr D.M. Roden Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes Circulation 105 2002 1943-1948
32. M.J. Ackerman D.J. Tester G.S. Jones M.L. Will C.R. Burrow M.E. Curran Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome Mayo Clin Proc 78 2003 1479-1487
33. M.J. Ackerman Splawski J. Makielski D.J. Terster M. Will K.W. Timothy M.T. Keating Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing Heart Rhythm 1 2004 600-607
34. P. Laitinen H. Fodstad K. Piippo H. Swan L. Toivonen M. Viitasalo J. Kaprio K. Kontula Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects Hum Mutat 15 2000 580-581
35. E. Pietila H. Fodstad E. Niskasaari P. Laitinen H. Swan M. Savolainen Y. Kesaniemi K. Kontula H. Huikuri Association between HERG K897T polymorphism and QT interval in middle-aged Finnish women J Am Coll Cardiol 40 2002 511-514
36. C.R. Bezinna A.O. Verkerk A. Busjahn O. Jeron J. Erdmann T.T. Koopmann Z.A. Bhuiyan R. Wilders M. Mannens H.L. Tan F.C. Luft H. Schunkert A.A.M. Wilde A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization Cardiovasc Res 59 2003 27-36
37. K.J. Paavonen H. Chapman P.J. Laitenen H. Fodstad K. Piippo H. Swan L. Toivonen M. Viitasalo K. Kontula M. Pasternack Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG) Cardiovasc Res 59 2003 603-611
38. B.D. Anson M.J. Ackerman D.J. Tester M.L. Will B.P. Delisle C.L. Anderson C.T. January Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels Am J Physiol Heart Circ Physiol 286 2004 H2434-H2441
39. L. Crotti A.L. Lundquist R. Insolia M. Pedrazzini C. Ferrandi G.M. De Ferrari A. Vicentini P. Yang D.M. Roden A.L. George Jr P.J. Schwartz KCNH2-K897T is a genetic modifier of latent congenital long QT syndrome Circulation 112 2005 1251-1258
40. P.J. Kannankeril K.J. Norris M.S. Gillani A.L. George Jr D.M. Roden A common polymorphism in KCNH2 (HERG) eliminates gender differences in drug-induced QT prolongation (abstr) Heart Rhythm 2 1S 2005 S145
41. Z. Sun P.M. Milos J.F. Thompson D.B. Lloyd A. Mank-Seymour J. Richmond J.S. Cordes J. Zhou Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes J Mol Cell Cardiol 37 2004 1031-1039
42. Ks potassium channels Circulation 100 Suppl I 1999 I-495
43. G.W. Abbott F. Sesti I. Splawski M.E. Buck M.H. Lehmann K.W. Timothy M.T. Keating S.A. Goldstein MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia Cell 97 1999 175-187
44. J.C. Makielski B. Ye C.R. Valdivia M.D. Pagel J.L. Pu D.J. Tester M.J. Ackerman A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels Circ Res 93 2003 821-828
45. B.-H. Tan C.R. Valdivia B.A. Rok B. Ye K.M. Ruwaldt D.J. Tester M.J. Ackerman J.C. Makielski Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants Heart Rhythm 2 2005 741-747
46. I. Splawski K.W. Timothy M. Tateyama C.E. Clancy A. Malhotra A.H. Beggs F.P. Cappuccio G.A. Sagnella R.S. Kass M.T. Keating Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia Science 297 2002 1333-1336
47. P.C. Viswanathan D.W. Benson J.R. Balser A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation J Clin Invest 1 2003 341-346
48. B. Ye C.R. Valdivia M.J. Ackerman J.C. Makielski A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation Physiol Genom 12 2003 187-193
49. D.M. Roden Cardiovascular pharmacogenomics Circulation 108 2003 3071-3074
50. M.E. Anderson S.M. Al-Khatib D.M. Roden R.M. Califf Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization. Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management Am Heart J 144 2002 769-781
51. I. Swenne P.T. Larsson Heart risk associated with weight loss in anorexia nervosa and eating disorders: Risk factors for QTc interval prolongation and dispersion Acta Paediatr 88 1999 304-309